Trial document



drksid header

  DRKS00000001

Trial Description

start of 1:1-Block title

Title

EWOG - MDS 98 Myelodysplastic Syndromes in Childhood
Prospective Study of the Diagnosis and Treatment
of Myelodysplastic Syndromes (MDS) in Childhood - EWOG-MDS 98

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

EWOG-MDS 98

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://www.ewog-mds.org

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Myelodysplastic Syndrome of childhood is a rare disorder that is charcetrized by a reduced production of blood cells and the risk of leukemia development. The prognosis for children diagnosed with MDS is unfavorable. The aim of the study is to introduce standard diagnostic tests and subsequently collect data about the frequency of the differnt subtypes of MDS. Furthermore, the survival of children with MDS should be improved by standardized treatment with chemotherapy and/or bone marrow transplantation.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Myelodysplastic Syndromes (MDS) in childhood are a heterogenous group of clonal stem cell disorders accounting for less than 10% of all hematological malignancies in childhood. MDS is characterized by peripheral blood cytopenia, ineffective hematopoiesis, dysplasia of all 3 cell lineages and a high risk of transformation in acute leukemia. Classification of MDS in Childhood has been confusing and inconsistent, while the FAB classification has generally been accepted for adults with MDS. Prognosis of most children with MDS is poor and there is no consensus in the literature concerning the optimal treatment strategy. In general, allogeneic stem cell transplantation (SCT) is the therapy of choice.
The primary objective of this multi-center non-randomized study is to facilitate the diagnostic procedures for all children and adolescents with MDS (study patients)by a standardized review of morphology and standardized cytogenetic and molecular analyses. All cases of MDS will be classified according to a modified FAB classification. Using this approach the frequency of the differnt FAB subtypes and cytogenetic and molecular abnormalities are to be assessed.
The secondary objective of the study is to improve the survival for children and adolescents with primary MDS(protocol patients) over that reported in the literature. In the presence of an HLA-matched family donor, early SCT is the treatment of choice for MDS patients of all FAB subtypes. SCT will be performed according to the ongoing EWOG-MDS study. In the presence of a bone marrow blast count > 15%, AML induction therapy is recommended prior to SCT. AML therapy for these protocol patients will be administered according to the National AML studies. For patients lacking an HLA-identical family donor, SCT from an unrelated volunteer is recommended, though AML therapy without SCT can be offered as an alternative treatment option.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000001
  •   2008/08/07
  •   2002/10/03
  •   yes
  •   Approved
  •   099/98, Ethik-Kommission der Albert-Ludwigs-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT00047268  (ClinicalTrials.gov)
  •   UKF000876  (Register Klinischer Studien des Universitätsklinikums Freiburg)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   D46.9 -  Myelodysplastic syndrome, unspecified
  •   Myelodysplastic syndrome, unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   1.Diagnosis for all children and adolescents with MDS (study patients)by a standardized review of morphology and standardized cytogenetic and molecular analyses
    2.Therapy: monitoring without treatment
  •   1.Diagnosis for all children and adolescents with MDS (study patients)by a standardized review of morphology and standardized cytogenetic and molecular analyses
    2.Therapy: treatment according to the national AML therapy
  •   1.Diagnosis for all children and adolescents with MDS (study patients)by a standardized review of morphology and standardized cytogenetic and molecular analyses
    2.Therapy: SCT will be performed according to the ongoing EWOG-MDS study
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Non-randomized controlled trial
  •   Open (masking not used)
  •   [---]*
  •   Active control (effective treament of control group)
  •   Treatment
  •   Parallel
  •   [---]*
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

- To evaluate the frequency of the different FAB subtypes by a standardized approach
- To evaluate the frequency of cytogenetic and molecular abnormalities

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- To improve survival for children and adolescents with primary MDS over that reported in the
literature
- To assess the rate of complete remission (CR) and the event-free survival (EFS) in children
with primary MDS treated according to AML therapy
- To evaluate the relapse rate, morbidity and mortality in children with primary MDS treated by
SCT
- To identify different subsets of patients with primary MDS benefiting from SCT or AML-type
therapy

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Denmark
  •   Sweden
  •   Norway
  •   Finland
  •   Iceland
  •   Netherlands
  •   Switzerland
  •   Austria
  •   Italy
  •   Czech Republic
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   1998/07/03
  •   850
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   no minimum age
  •   18   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

All children and adolescents with MDS under the age of 19 diagnosed between July 1998 and June 2002 are registered as study patients.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

- Children with Down syndrome
- Children with the following cytogenetic or molecular abnormalities:
t(8;21)(q22;q22) [AML1/ETO fusion gene]
t(15;17)(q22;q12) [PML/RAR´´ rearrangement]
inv(16)(p13q22) [CBF$/MYH11rearrangement]
- Children with the typical clinical and cytogenetic features of AML FAB M7 who present with < 30% blasts in the BM and PB

- Concomitant illness precluding therapy according to protocol
- No informed consent by the patient or legal guardian
- Morphological diagnosis could not be confirmed

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Freiburg
    • Hugstetter Str. 49
    • 79095  Freiburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Zentrum für Kinder- und Jugendmedizin des Universitätsklinikums Freiburg, Klinik IV, Pädiatrische Hämatologie/Onkologie
    • Ms.  Prof. Dr. med  Charlotte  Niemeyer 
    • Mathildenstr.1
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Zentrum für Kinder- und Jugendmedizin des Universitätsklinikums Freiburg, Klinik IV, Pädiatrische Hämatologie/Onkologie
    • Ms.  Prof. Dr. med  Charlotte  Niemeyer 
    • Mathildenstr.1
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Zentrum für Kinder- und Jugendmedizin des Universitätsklinikums Freiburg, Klinik IV, Pädiatrische Hämatologie/Onkologie
    • Ms.  Prof. Dr. med  Charlotte  Niemeyer 
    • Mathildenstr.1
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2006/12/31
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.